LPCN vs. DRRX, THTX, ENLV, NNVC, JAN, BIOR, ACST, UBX, VIRX, and IPA
Should you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include DURECT (DRRX), Theratechnologies (THTX), Enlivex Therapeutics (ENLV), NanoViricides (NNVC), JanOne (JAN), Biora Therapeutics (BIOR), Acasti Pharma (ACST), Unity Biotechnology (UBX), Viracta Therapeutics (VIRX), and ImmunoPrecise Antibodies (IPA). These companies are all part of the "pharmaceutical preparations" industry.
Lipocine (NASDAQ:LPCN) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, community ranking, earnings, dividends, profitability, analyst recommendations, valuation and risk.
DURECT has a consensus price target of $27.50, suggesting a potential upside of 2,856.99%. Given DURECT's higher possible upside, analysts plainly believe DURECT is more favorable than Lipocine.
Lipocine received 27 more outperform votes than DURECT when rated by MarketBeat users. Likewise, 70.14% of users gave Lipocine an outperform vote while only 65.56% of users gave DURECT an outperform vote.
Lipocine has higher earnings, but lower revenue than DURECT. Lipocine is trading at a lower price-to-earnings ratio than DURECT, indicating that it is currently the more affordable of the two stocks.
In the previous week, DURECT had 19 more articles in the media than Lipocine. MarketBeat recorded 20 mentions for DURECT and 1 mentions for Lipocine. DURECT's average media sentiment score of 0.32 beat Lipocine's score of 0.00 indicating that DURECT is being referred to more favorably in the news media.
9.1% of Lipocine shares are owned by institutional investors. Comparatively, 28.0% of DURECT shares are owned by institutional investors. 6.1% of Lipocine shares are owned by company insiders. Comparatively, 4.3% of DURECT shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Lipocine has a net margin of 0.00% compared to DURECT's net margin of -279.77%. Lipocine's return on equity of -37.62% beat DURECT's return on equity.
Lipocine has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, DURECT has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.
Summary
Lipocine beats DURECT on 9 of the 17 factors compared between the two stocks.
Get Lipocine News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipocine Competitors List
Related Companies and Tools
